RET融合基因在非小细胞肺癌诊治中的意义

Lung cancer is the leading cause of cancer-related death worldwide, molecular target therapy has become a hot research direction of non-small cell lung cancer (NSCLC) treatment. RET fusion gene with an identifiable clinical pathological features, is present in some subsets of lung cancer, and its tr...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2013
Materias:
综述
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000613/
https://www.ncbi.nlm.nih.gov/pubmed/24229630
http://dx.doi.org/10.3779/j.issn.1009-3419.2013.11.11
_version_ 1783331787691261952
collection PubMed
description Lung cancer is the leading cause of cancer-related death worldwide, molecular target therapy has become a hot research direction of non-small cell lung cancer (NSCLC) treatment. RET fusion gene with an identifiable clinical pathological features, is present in some subsets of lung cancer, and its treatment is effective by RET inhibitor, suggesting that RET fusion gene may be a new target for individualized treatment to the subgroup of NSCLC. This article reviews the structural characteristics of RET fusion gene and expression model in clinical samples, and treatment of NSCLC.
format Online
Article
Text
id pubmed-6000613
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher 中国肺癌杂志编辑部
record_format MEDLINE/PubMed
spelling pubmed-60006132018-07-06 RET融合基因在非小细胞肺癌诊治中的意义 Zhongguo Fei Ai Za Zhi 综述 Lung cancer is the leading cause of cancer-related death worldwide, molecular target therapy has become a hot research direction of non-small cell lung cancer (NSCLC) treatment. RET fusion gene with an identifiable clinical pathological features, is present in some subsets of lung cancer, and its treatment is effective by RET inhibitor, suggesting that RET fusion gene may be a new target for individualized treatment to the subgroup of NSCLC. This article reviews the structural characteristics of RET fusion gene and expression model in clinical samples, and treatment of NSCLC. 中国肺癌杂志编辑部 2013-11-20 /pmc/articles/PMC6000613/ /pubmed/24229630 http://dx.doi.org/10.3779/j.issn.1009-3419.2013.11.11 Text en 版权所有©《中国肺癌杂志》编辑部2013 https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/
spellingShingle 综述
RET融合基因在非小细胞肺癌诊治中的意义
title RET融合基因在非小细胞肺癌诊治中的意义
title_full RET融合基因在非小细胞肺癌诊治中的意义
title_fullStr RET融合基因在非小细胞肺癌诊治中的意义
title_full_unstemmed RET融合基因在非小细胞肺癌诊治中的意义
title_short RET融合基因在非小细胞肺癌诊治中的意义
title_sort ret融合基因在非小细胞肺癌诊治中的意义
topic 综述
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000613/
https://www.ncbi.nlm.nih.gov/pubmed/24229630
http://dx.doi.org/10.3779/j.issn.1009-3419.2013.11.11

Ejemplares similares